AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 191 min read$GRCE

Opaleye Management Inc. purchased $24K of GRCE (indirect holdings)

Opaleye Management Inc. purchased 11,608 indirectly-held shares of Grace Therapeutics, Inc. (GRCE) at $2.09 on 2026-08-14.

Original reporting
SEC EDGAR · Opaleye Management Inc.
Published Aug 19, 2026, 11:44 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 11:55 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$GRCE
Neutral
high confidence
Mentioned
$GRCE
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GRCENeutralLow
01

Why it matters

The purchase adds 11,608 shares to the insider's holdings, bringing total to 2.76 million shares.

02

Market read

Minor insider purchase with limited trading relevance.

03

What to watch

Potential future larger purchases by the same insider are not disclosed.

Relevance 3/10Novelty 4/10Timing: filed 2026-08-19

Background

Form 4 filings disclose insider transactions; this filing reports a modest purchase by a 10% owner.

Company-level read

Ticker impact

$GRCENeutralHigh confidence
Context

Opaleye Management Inc. purchased 11,608 shares of Grace Therapeutics for $24,206, filing a Form 4 on 2026-08-19.

Expected impact

minimal impact

Evidence & confidence

The transaction size is under $25k and represents a tiny fraction of outstanding shares, so market reaction is expected to be negligible.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Even small insider buys can signal confidence, but the amount is too trivial to act on.

Key entities

  • Company
    Grace Therapeutics, Inc.

    Biotech company whose ticker is GRCE.

  • Insider
    Opaleye Management Inc.

    10% owner of Grace Therapeutics filing the purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GRCE insider trading history →

Related articles

AUG 13
$GRCEMed

Grace Therapeutics, Inc. (GRCE): Results of Operations and Financial Condition

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99. 1 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104

SEC EDGAR 8-K6 min
JUN 18
$GRCEMed

Grace Therapeutics, Inc. (GRCE): Results of Operations and Financial Condition

Grace Therapeutics, Inc. (GRCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ef20076145_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Pr

SEC EDGAR 8-K4 min